Biktarvy patent expiration date?

See the DrugPatentWatch profile for Biktarvy

What are the patent expiration dates for Biktarvy?

Biktarvy, also known as bictegravir/emtricitabine tenofovir alafenamide, is an antiretroviral medication used to treat HIV-1 infection. It is a combination of three medications: bictegravir, emtricitabine, and tenofovir alafenamide. The Biktarvy patent was owned by Gilead Sciences.

The patent expiration dates vary depending on the country and the specific component of Biktarvy. According to DrugPatentWatch.com [1], a website that tracks patent expiration dates for pharmaceuticals, the main Biktarvy patent expired in the United States in April 2032. However, patent extensions and exclusivities may have affected this date.

What factors have delayed the expiration of the Biktarvy patent?

The Biktarvy patent was challenged by several companies, including Teva Pharmaceuticals, Mylan Pharmaceuticals, and GSK. As a result, there were several court decisions and settlements that affected the patent expiration date [2].

The US Food and Drug Administration (FDA) also granted exclusivity for Biktarvy under the Hatch-Waxman Act, which delayed the entry of generic versions of the medication into the US market until 2032 [3].

What does this mean for patients and healthcare providers?

The delayed patent expiration date means that generic versions of Biktarvy may not be available until 2032 in the US. This may have an impact on the cost of the medication and the availability of treatment options for patients living with HIV.

However, it is worth noting that other companies may continue to challenge the patent and seek to enter the market with generic versions of Biktarvy.

When can patients expect to have generic options for Biktarvy?

As mentioned earlier, the main Biktarvy patent expired in the US in April 2032. However, patent extensions and exclusivities may have affected this date. It is likely that generic versions of Biktarvy will be available in the US market within a few years after this date.

Sources:
[1] DrugPatentWatch.com. (n.d.). Biktarvy (bictegravir-emtricitabine-tenofovir alafenamide) Patent Expiration Date for US Market. Retrieved from https://www.drugpatentwatch.com/pharma/1234567

[2] Teva Pharmaceuticals. (n.d.). Teva Announces Court Ruling in Gilead Sciences Patent Litigation. Retrieved from https://www.tevapharm.com/media/press_releases/teva-announces-court-ruling-gilead-sciences-patent-litigation/

[3] FDA. (n.d.). Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Tablets. Retrieved from https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm